Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Perrigo Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Perrigo kazanç ve gelirin sırasıyla yıllık 59.3% ve 3.2% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 60.6% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 5.5% olacağı tahmin edilmektedir.

Anahtar bilgiler

59.3%

Kazanç büyüme oranı

63.0%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	23.8%
Gelir büyüme oranı	3.2%
Gelecekteki özkaynak getirisi	5.5%
Analist kapsamı	Low
Son güncelleme	04 Oct 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Improved Revenues Required Before Perrigo Company plc (NYSE:PRGO) Shares Find Their Feet

Jul 03

These 4 Measures Indicate That Perrigo (NYSE:PRGO) Is Using Debt Extensively

May 29

Benign Growth For Perrigo Company plc (NYSE:PRGO) Underpins Its Share Price

Mar 27

These 4 Measures Indicate That Perrigo (NYSE:PRGO) Is Using Debt Extensively

Feb 01

The Market Doesn't Like What It Sees From Perrigo Company plc's (NYSE:PRGO) Revenues Yet

Dec 28

Perrigo's New Chapter: Its Bold Turnaround Plan Is Worth Buying

Nov 15

The Prognosis For Perrigo

Aug 30

Perrigo Outlook Healed By Repositioning

Jun 12

Perrigo raises dividend by 5% to $0.273/share

Feb 21

Perrigo: Still Languishing But Short-Term Trend Offers Encouragement

Jan 18

Perrigo Non-GAAP EPS of $0.56 misses by $0.11, revenue of $1.1B misses by $40M, lowers FY adj. EPS guidance

Nov 08

Perrigo to invest $170M to expand baby formula manufacturing, buys Nestlé Gateway plant

Nov 01

Perrigo Company plc Is Back On Track

Oct 20

Perrigo to face FDA AdCom meeting for OTC contraceptive

Sep 12

Perrigo responds to 'misleading and inaccurate information' on Zantac claims

Aug 17

Perrigo reports Q2 mixed results; raises FY22 organic net sales growth outlook

Aug 09

Perrigo declares $0.26 dividend

Aug 02

Perrigo: HRA Acquisition To Drive Significant Growth

Jul 20

Perrigo unit seeks FDA over-the-counter approval for birth control pill Opill

Jul 11

Perrigo: The Longer The Base The Higher In Space

Apr 12

Kazanç ve Gelir Büyüme Tahminleri

NYSE:PRGO - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	4,842	184	537	668	5
12/31/2025	4,681	91	608	626	5
12/31/2024	4,468	-166	342	335	5
6/29/2024	4,428	-114	234	341	N/A
3/30/2024	4,556	1	301	385	N/A
12/31/2023	4,656	-4	324	406	N/A
9/30/2023	4,654	11	311	383	N/A
7/1/2023	4,630	-57	255	317	N/A
4/1/2023	4,559	-131	152	248	N/A
12/31/2022	4,452	-131	214	307	N/A
10/1/2022	4,401	-86	-102	16	N/A
7/2/2022	4,344	-88	162	301	N/A
4/2/2022	4,203	-135	112	235	N/A
12/31/2021	4,139	-131	-63	156	N/A
10/2/2021	4,087	-215	128	372	N/A
7/3/2021	4,047	-135	-157	91	N/A
4/3/2021	4,015	-11	214	465	N/A
12/31/2020	4,088	44	435	636	N/A
9/26/2020	4,358	77	371	615	N/A
6/27/2020	4,546	143	406	692	N/A
3/28/2020	4,746	140	136	465	N/A
12/31/2019	3,870	159	104	388	N/A
9/28/2019	4,710	247	272	493	N/A
6/29/2019	4,652	87	307	497	N/A
3/30/2019	4,689	114	374	515	N/A
12/31/2018	4,732	131	469	593	N/A
9/29/2018	4,820	123	505	616	N/A
6/30/2018	4,918	235	596	668	N/A
3/31/2018	4,969	129	N/A	677	N/A
12/31/2017	4,946	120	N/A	699	N/A
9/30/2017	4,994	-1,313	N/A	688	N/A
7/1/2017	5,025	-2,947	N/A	711	N/A
4/1/2017	5,127	-3,412	N/A	751	N/A
12/31/2016	5,281	-4,013	N/A	655	N/A
10/1/2016	5,308	-2,872	N/A	596	N/A
7/2/2016	5,320	-1,021	N/A	431	N/A
4/2/2016	5,395	-509	N/A	683	N/A
12/31/2015	5,015	-2	N/A	764	N/A
9/26/2015	4,997	144	N/A	1,139	N/A
6/27/2015	4,227	136	N/A	855	N/A
3/28/2015	4,217	203	N/A	1,028	N/A
12/27/2014	4,172	347	N/A	941	N/A
9/27/2014	4,079	190	N/A	790	N/A
6/28/2014	3,914	233	N/A	633	N/A
3/29/2014	3,884	192	N/A	575	N/A
12/28/2013	3,800	256	N/A	545	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: PRGO önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 2.5% ) daha hızlı bir büyüme olarak değerlendiriliyor.

Kazançlar ve Piyasa: PRGO önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.

Yüksek Büyüme Kazançları: PRGO önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.

Gelir ve Pazar: PRGO şirketinin gelirinin (yıllık 3.2% ) US pazarından (yıllık 8.7% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: PRGO şirketinin gelirinin (yıllık 3.2% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: PRGO 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 5.5 %).

Perrigo Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus EPS estimates fall by 288%

Perrigo Company plc Reaffirms Earnings Guidance for 2024

Consensus EPS estimates have been downgraded.

Price target decreased by 13% to US$38.75

Consensus EPS estimates fall by 24%

Perrigo Company plc Updates Earnings Guidance for the Fiscal 2023

Recent updates

Perrigo Company plc Appoints Charles Atkinson, as Executive Vice President, General Counsel and Secretary

Upcoming dividend of US$0.28 per share

Advisor recently sold US$969k worth of stock

Perrigo (NYSE:PRGO) Is Due To Pay A Dividend Of $0.276

Perrigo Company plc Appoints David Ball as Executive Vice President and Chief Brand and Digital Officer

The Play On Perrigo

Perrigo (NYSE:PRGO) Has Announced A Dividend Of $0.276

Second quarter dividend of US$0.28 announced

Second quarter 2024 earnings released: US$0.77 loss per share (vs US$0.066 profit in 2Q 2023)

Perrigo Company plc Reports Impairment Charges for the Second Quarter Ended June 29, 2024

Perrigo Company plc to Report Q2, 2024 Results on Aug 02, 2024

President exercised options to buy US$477k worth of stock.

Esteve Healthcare S.L. completed the acquisition of HRA Pharma Rare Diseases America, LLC from Perrigo Company plc.

Improved Revenues Required Before Perrigo Company plc (NYSE:PRGO) Shares Find Their Feet

Perrigo Company plc Appoints Todd Penegor as Member of Board and to Serve on Audit Committee, Effective June 21, 2024

Perrigo Company plc Announces Executive Changes

These 4 Measures Indicate That Perrigo (NYSE:PRGO) Is Using Debt Extensively

Upcoming dividend of US$0.28 per share

Consensus EPS estimates fall by 288%

Perrigo Company plc Reaffirms Earnings Guidance for 2024

New major risk - Financial position

First quarter 2024 earnings released: EPS: US$0.03 (vs US$0.008 loss in 1Q 2023)

Fourth quarter dividend of US$0.28 announced

Perrigo Company plc Announces Quarterly Dividend, Payable on June 18, 2024

Esteve Healthcare S.L. agreed to acquire HRA Pharma Rare Diseases America, LLC from Perrigo Company plc (NYSE:PRGO) for approximately €280 million.

Perrigo Company plc to Report Q1, 2024 Results on May 07, 2024

Benign Growth For Perrigo Company plc (NYSE:PRGO) Underpins Its Share Price

Perrigo Company plc, Annual General Meeting, May 02, 2024

Perrigo Company plc Announces Erica L. Mann Not to Stand for Re-Election to its Board of Directors

Consensus EPS estimates have been downgraded.

Full year 2023 earnings: EPS misses analyst expectations

Perrigo Company plc Reports Impairment Charges for the Fourth Quarter Ended December 31, 2023

Price target decreased by 13% to US$38.75

Consensus EPS estimates fall by 24%

Perrigo Company plc Increases its Quarterly Dividend, Payable on March 26, 2024

Perrigo Company plc to Report Q4, 2023 Results on Feb 27, 2024

These 4 Measures Indicate That Perrigo (NYSE:PRGO) Is Using Debt Extensively

The Market Doesn't Like What It Sees From Perrigo Company plc's (NYSE:PRGO) Revenues Yet

Upcoming dividend of US$0.27 per share at 3.6% yield

President recently bought US$319k worth of stock

Perrigo's New Chapter: Its Bold Turnaround Plan Is Worth Buying

Perrigo Company plc Updates Earnings Guidance for the Fiscal 2023

Perrigo Company plc to Report Q3, 2023 Results on Nov 07, 2023

Perrigo Company plc Announces Executive Changes

The Prognosis For Perrigo

Perrigo Company plc Reaffirms Earnings Guidance for the Fiscal 2023

Perrigo Company plc to Report Q2, 2023 Results on Aug 08, 2023

Perrigo Company plc Announces U.S. FDA Approval for Opill OTC Daily Oral Contraceptive

Perrigo Outlook Healed By Repositioning

Perrigo Company plc Appoints Patrick Lockwood-Taylor as Its New Chief Executive Officer

Perrigo Announces U.S. FDA Approval for Nicotine Coated Mint Lozenge

Perrigo Company plc Announces FDA Approval of Opill®? for Over-The-Counter Use

Perrigo Company plc Reaffirms Sales Guidance for the Fiscal Year 2023

Perrigo Announces Quarterly Dividend, Payable on June 20, 2023

Perrigo raises dividend by 5% to $0.273/share

Perrigo Company plc to Report Q4, 2022 Results on Feb 27, 2023

Theodore R. Samuels Not to Stand for Re-Election to the Perrigo Company plc's Board of Directors

Perrigo: Still Languishing But Short-Term Trend Offers Encouragement

Perrigo Company plc Provides Earnings Guidance for the Fiscal Year 2022

Perrigo Non-GAAP EPS of $0.56 misses by $0.11, revenue of $1.1B misses by $40M, lowers FY adj. EPS guidance

Perrigo Company plc Announces Quarterly Dividend, Payable on December 20, 2022

Perrigo Company plc (NYSE:PRGO) acquired Good Start Packaging, Inc. from Nestle Canada Inc.

Perrigo to invest $170M to expand baby formula manufacturing, buys Nestlé Gateway plant

Perrigo Company plc to Report Q3, 2022 Results on Nov 08, 2022

Perrigo Company plc Is Back On Track

Perrigo to face FDA AdCom meeting for OTC contraceptive

Perrigo Company plc Announces Litigation Update

Perrigo responds to 'misleading and inaccurate information' on Zantac claims

Perrigo Company Revised Earnings Guidance for the Full Year of 2022